Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy

Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference... NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy Thomas J. Lynch, Jr,* George R. Blumenschein, Jr,† Jeffrey A. Engelman,* Igor Espinoza-Delgado,‡ Ramaswamy Govindan,§ Jeff Hanke, Nasser H. Hanna,¶ John V. Heymach,† Fred R. Hirsch,# Pasi A. Janne,** Rogerio C. Lilenbaum,†† Ronald B. Natale,‡‡ Gregory J. Riely,§§ Lecia V. Sequist,* Geoffrey I. Shapiro,** Alice Shaw, Frances A. Shepherd,¶¶ Mark Socinski,## A. Gregory Sorensen,*** Heather A. Wakelee,††† and Aaron Weitzman‡‡‡ of patients? (3) What models do we use to predict clinical response The promise of effective targeted therapy for lung cancer requires and identify effective combinations? And (4) how do we bring rigorous identification of potential targets combined with intensive combination regimens to the clinic, particularly when the agents are discovery and development efforts aimed at developing effective not yet approved individually and may be under development from “drugs” for these targets. We now recognize that getting the right different companies? The Fifth Cambridge Conference on Novel drug to the right target in the right patient is more complicated than Agents in the Treatment of Lung Cancer was held in Cambridge, one could http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy

Weitzman, Aaron
Journal of Thoracic Oncology , Volume 3 – Jun 1, 2008
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/summary-statement-novel-agents-in-the-treatment-of-lung-cancer-colon-Tqwmsl9zrp

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy Thomas J. Lynch, Jr,* George R. Blumenschein, Jr,† Jeffrey A. Engelman,* Igor Espinoza-Delgado,‡ Ramaswamy Govindan,§ Jeff Hanke, Nasser H. Hanna,¶ John V. Heymach,† Fred R. Hirsch,# Pasi A. Janne,** Rogerio C. Lilenbaum,†† Ronald B. Natale,‡‡ Gregory J. Riely,§§ Lecia V. Sequist,* Geoffrey I. Shapiro,** Alice Shaw, Frances A. Shepherd,¶¶ Mark Socinski,## A. Gregory Sorensen,*** Heather A. Wakelee,††† and Aaron Weitzman‡‡‡ of patients? (3) What models do we use to predict clinical response The promise of effective targeted therapy for lung cancer requires and identify effective combinations? And (4) how do we bring rigorous identification of potential targets combined with intensive combination regimens to the clinic, particularly when the agents are discovery and development efforts aimed at developing effective not yet approved individually and may be under development from “drugs” for these targets. We now recognize that getting the right different companies? The Fifth Cambridge Conference on Novel drug to the right target in the right patient is more complicated than Agents in the Treatment of Lung Cancer was held in Cambridge, one could

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2008

There are no references for this article.